Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Relmada Therapeutics (RLMD) Tops Q1 EPS by 5c
May 12, 2021 4:33 PM EDTRelmada Therapeutics (NASDAQ: RLMD) reported Q1 EPS of ($1.34), $0.05 better than the analyst estimate of ($1.39).
"We continue to advance the development of our lead product candidate, REL-1017, for the treatment of major depressive disorder (MDD)," said Sergio Traversa, Relmada's Chief Executive Officer. "The RELIANCE... More
